FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BESSER JAMES E
2. Issuer Name and Ticker or Trading Symbol

Processa Pharmaceuticals, Inc. [ PCSA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
_____ Officer (give title below)    __X__ Other (specify below)
See Remarks
(Last)          (First)          (Middle)

53 PALMERAS STREET, CARIBE PLAZA BUILDING, 6TH FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)

4/6/2021
(Street)

SAN JUAN, PR 00901
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

4/8/2021 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 par value 4/6/2021  S  31771 D$10.91 1064300 I See footnotes (1)(2)
Common Stock, $0.01 par value 4/7/2021  S  16000 D$10.67 1048300 I See footnotes (1)(2)
Common Stock, $0.01 par value 4/8/2021  S  400000 D$10.76 648300 I See footnotes (1)(2)
Common Stock, $0.01 par value         405000 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) These securities are directly owned by Manchester Explorer, L.P. and JEB Partners, L.P. These securities are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P.; these securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC.
(2) The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks:
As of as of April 07, 2021, the Reporting Person is no longer subject to the reporting requirements of Section 16 of the Securities Exchange Act of 1934. The original Form 4, filed April 8, 2021, is being amended by this Form 4 amendment solely to correct an administrative error, which mistakenly inverted the ownership codes in Table I, Item 6, showing indirectly held shares as directly held and vice versa.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
BESSER JAMES E
53 PALMERAS STREET
CARIBE PLAZA BUILDING, 6TH FLOOR
SAN JUAN, PR 00901



See Remarks

Signatures
/s/ James E. Besser5/5/2021
**Signature of Reporting PersonDate

Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Processa Pharmaceuticals Charts.
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Processa Pharmaceuticals Charts.